The $3.9 Million Shot That Could Save Kids With No Other Options
For decades, families with Sanfilippo syndrome were told to take their kids home and love them. Now a $3.9 million gene therapy from Ultragenyx is the first FDA-approved treatment for this fatal childhood brain disease, and it's part of a wave that's reshaping rare disease medicine.
Imagine taking your toddler to the doctor because they're not hitting milestones. They're a little behind on speech, a little slow to learn new things. You assume they'll catch up. Then you get a diagnosis that sounds like a death sentence: your child has a progressive brain disease, there's no approved treatment, and they probably won't live past their teenage years.
For decades, that was the reality for families facing Sanfilippo syndrome. Doctors would tell parents to take their kids home and love them. That was the medical plan.
As of last Friday, there's finally a different answer.
A First-Ever Treatment, Decades in the Making
The FDA approved FAYUVI (rebisufligene etisparvovec-hopf), the first gene therapy for pediatric patients with Sanfilippo syndrome type A. The drug, made by Ultragenyx Pharmaceutical, is designed to treat the neurological devastation caused by this ultra-rare genetic disorder. It's also the first FDA-approved treatment of any kind for the disease.
Let that sink in. Before last week, if your child had Sanfilippo syndrome, the number of approved therapies available was exactly zero.
Sanfilippo syndrome (technically called mucopolysaccharidosis type IIIA, or MPS IIIA) is a lysosomal storage disorder. In plain English: the body's cellular recycling system is broken. Cells can't properly break down a sugar molecule called heparan sulfate, so it builds up like trash in a landfill. Except the landfill is your child's brain. Over time, the accumulation causes progressive cognitive decline, behavioral problems, and ultimately dementia, all in kids who seemed perfectly healthy at birth.
The Numbers Behind the Nightmare
Sanfilippo syndrome affects roughly 1 in 70,000 live births, though the true number is likely higher because many cases are diagnosed late or missed entirely. Symptoms usually appear between ages 1 and 4. Most patients don't survive past their second decade of life.
The disease follows a cruel trajectory. Kids develop normally for a while, then plateau, then slowly lose every skill they've gained. Walking, talking, recognizing their parents: it all fades. The major causes of death are respiratory complications and infections.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This is one of those diseases where the rarity makes it more devastating, not less. Because so few patients exist, there's been little commercial incentive to develop treatments. The families who've been fighting for research funding have been doing it largely on their own, holding fundraisers and begging pharmaceutical companies to pay attention.
From a University Lab to an FDA Approval
FAYUVI's origin story stretches back years, and it involves the kind of winding path that's become familiar in rare disease drug development.
The therapy was co-invented by Haiyan Fu, PhD, and Doug McCarty, PhD, during their academic work at Ohio State University and Nationwide Children's Hospital. In 2013, Abeona Therapeutics licensed the program and began advancing it through clinical trials under the name ABO-102.
Then came the handoff. In May 2022, Ultragenyx acquired global rights to the program and took over development. They shepherded it through the final stages of clinical testing, filed the biologics license application, and secured Priority Review from the FDA in February 2025.
Along the way, the program collected an impressive string of regulatory designations: Orphan Drug, Fast Track, Rare Pediatric Disease, and Breakthrough Therapy in the U.S., plus PRIME and Orphan Medicinal Product designations in Europe. Think of these as express lane passes that help speed up the review process for drugs targeting serious conditions with major unmet needs.
What the Trial Actually Showed
The pivotal clinical program, called Transpher A, tested FAYUVI's ability to slow or stop the neurological decline that defines Sanfilippo syndrome. Because you can't ethically give kids with a fatal disease a placebo, the trial compared treated patients against natural history data (essentially, documented records of how untreated patients typically decline over time).
The results were striking on two levels. First, the biomarker: treated patients showed a roughly 64% reduction in cerebrospinal fluid heparan sulfate, the toxic sugar that accumulates in the brain. That's like clearing two-thirds of the garbage out of the landfill.
Second, and more importantly, the functional outcomes. FAYUVI produced statistically significant improvements in cognition, receptive communication, and expressive communication (measured by Bayley-III scores) compared to untreated patients. In the age range where untreated kids typically plateau or decline, treated children were maintaining or even improving their developmental skills.
The benefit was especially pronounced in younger patients who were treated before advanced neurodegeneration had set in. Which makes intuitive sense: it's easier to protect a house from fire damage if you call the fire department early rather than after the roof has collapsed.
On the safety front, the most common side effect was elevated liver enzymes, mostly mild (Grade 1 or 2), and they resolved on their own. No serious drug-related adverse events were reported during the follow-up period. For a gene therapy, that's a remarkably clean safety profile.
The Price Tag That Will Make Your Eyes Water
FAYUVI launched at approximately $3.9 million per patient. Yes, million. With an M.
Before you spit out your coffee, consider the context. This is a one-time treatment for a fatal childhood disease that previously had no options whatsoever. The patient population is tiny (we're talking hundreds of patients in the U.S., not thousands). Manufacturing a gene therapy is extraordinarily complex and expensive. And the alternative, watching a child slowly lose all cognitive function and die, carries its own enormous costs, both financial and human.
That said, $3.9 million is still a staggering number. It's consistent with the pricing trend for ultra-rare pediatric gene therapies; Lenmeldy, approved in March 2024 for metachromatic leukodystrophy (another lysosomal storage disorder), set a similar precedent at the multi-million-dollar level.
The big question isn't whether the drug works. It's whether families can actually get it. Coverage for therapies in this price range remains challenging. Patient pools are tiny, long-term durability data is still limited at launch, and payers don't have a great playbook for one-time treatments that cost more than most houses.
A Pattern That's Starting to Look Like a Movement
FAYUVI doesn't exist in a vacuum. It's part of a growing wave of gene therapy approvals for previously untreatable childhood genetic diseases. Lenmeldy for MLD in 2024. FAYUVI for Sanfilippo in 2026.
The pattern is clear: the FDA is increasingly willing to approve one-time gene therapies for ultra-rare pediatric neurological conditions, even when the clinical programs are small and rely on natural history comparisons rather than traditional placebo-controlled trials. That's a meaningful signal for the dozens of similar programs in development across the industry.
It also validates a thesis that rare disease advocates have been pushing for years: just because a disease is rare doesn't mean the patients don't deserve cutting-edge science. Every one of these approvals builds a precedent that makes the next one a little more achievable.
What This Means for the Families
The Sanfilippo community's reaction was, predictably, overwhelming. The Cure Sanfilippo Foundation and the National MPS Society called it a historic milestone, the culmination of decades of fundraising, collaboration, and perseverance. Nationwide Children's Hospital publicly celebrated the approval as validation of the foundational research that started in their labs.
But the quote that sticks with me is simpler than any of that. Families said the approval means they'll no longer be told just to "take their kids home and love them." Now they'll be given hope and an action plan for treatment.
Ultragenyx also received a Priority Review Voucher alongside the approval. These vouchers, awarded for rare pediatric disease approvals, can be sold to other companies (often for hundreds of millions of dollars) or used to fast-track a future FDA submission. It's a nice financial incentive that helps offset the economics of developing drugs for diseases that affect a few hundred patients.
The Bottom Line
FAYUVI is expensive. It treats a disease most people have never heard of. Its clinical program was small by pharmaceutical standards. And yet this approval matters enormously.
It matters because it proves gene therapy can work in lysosomal storage disorders. It matters because it gives hope to families who had none. And it matters because it extends a pattern of the FDA greenlighting transformative treatments for the smallest, most vulnerable patient populations.
The $3.9 million price will dominate headlines. But for the parents who just learned their child has Sanfilippo syndrome, the headline is different: for the first time ever, there's something we can actually do.
4 min read
Parkinson's Gets Its First New Type of Dopamine Drug in Decades
The FDA just approved the first Parkinson's drug to selectively target D1/D5 dopamine receptors, a mechanism no other marketed therapy uses. AbbVie paid $8.7 billion for this drug; now it needs to prove the bet was worth it.
